CN1615297A - 治疗精神分裂症和抑郁等疾病的苯氧基－哌啶 - Google Patents

治疗精神分裂症和抑郁等疾病的苯氧基－哌啶 Download PDF

Info

Publication number
CN1615297A
CN1615297A CNA028272544A CN02827254A CN1615297A CN 1615297 A CN1615297 A CN 1615297A CN A028272544 A CNA028272544 A CN A028272544A CN 02827254 A CN02827254 A CN 02827254A CN 1615297 A CN1615297 A CN 1615297A
Authority
CN
China
Prior art keywords
formula
compound
solvates
stereoisomers
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028272544A
Other languages
English (en)
Chinese (zh)
Inventor
G·霍尔策曼
H·普鲁克尔
K·席曼
J·莱布罗克
H·格赖纳
C·比格尔
L·冯梅赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1615297A publication Critical patent/CN1615297A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028272544A 2002-01-17 2002-12-17 治疗精神分裂症和抑郁等疾病的苯氧基－哌啶 Pending CN1615297A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10201550A DE10201550A1 (de) 2002-01-17 2002-01-17 Phenoxy-Piperidine
DE10201550.3 2002-01-17

Publications (1)

Publication Number Publication Date
CN1615297A true CN1615297A (zh) 2005-05-11

Family

ID=7712334

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028272544A Pending CN1615297A (zh) 2002-01-17 2002-12-17 治疗精神分裂症和抑郁等疾病的苯氧基－哌啶

Country Status (11)

Country Link
US (2) US20050131021A1 (https=)
EP (1) EP1465868A1 (https=)
JP (1) JP4727925B2 (https=)
CN (1) CN1615297A (https=)
AU (1) AU2002358735B9 (https=)
CA (1) CA2473409C (https=)
DE (1) DE10201550A1 (https=)
HU (1) HUP0500497A2 (https=)
PL (1) PL373946A1 (https=)
WO (1) WO2003059882A1 (https=)
ZA (1) ZA200406504B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050861A1 (es) * 2003-12-03 2005-12-10 Glaxo Group Ltd Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8787440B2 (en) * 2008-07-25 2014-07-22 Qualcomm Incorporated Determination of receive data values
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776293A (en) * 1950-08-09 1957-01-01 Nopco Chem Co Improved hydrogenation process
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5202346A (en) * 1992-02-25 1993-04-13 American Home Products Corporation Piperidinyl and piperazinyl derivatives
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
IL128524A0 (en) * 1996-08-15 2000-01-31 Schering Corp Ether muscarinic antagonists
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2002363159A (ja) * 2001-04-05 2002-12-18 Sankyo Co Ltd ベンズアミジン誘導体
AU2003248571A1 (en) * 2002-05-24 2003-12-12 Neurion Pharmaceuticals, Inc. Methods of determining precise herg interactions and altering compounds based on said interactions

Also Published As

Publication number Publication date
AU2002358735A1 (en) 2003-07-30
AU2002358735B2 (en) 2009-03-12
JP2005514457A (ja) 2005-05-19
JP4727925B2 (ja) 2011-07-20
AU2002358735B9 (en) 2009-04-09
US20090247584A1 (en) 2009-10-01
DE10201550A1 (de) 2003-07-31
CA2473409C (en) 2011-09-27
PL373946A1 (en) 2005-09-19
HUP0500497A2 (hu) 2005-08-29
CA2473409A1 (en) 2003-07-24
US20050131021A1 (en) 2005-06-16
ZA200406504B (en) 2005-09-15
EP1465868A1 (de) 2004-10-13
WO2003059882A1 (de) 2003-07-24

Similar Documents

Publication Publication Date Title
CN1615297A (zh) 治疗精神分裂症和抑郁等疾病的苯氧基－哌啶
CN1298324C (zh) 萘啶衍生物、其制备方法及其作为磷酸二酯酶同功酶4(pde4)抑制剂的应用
CN1319958C (zh) 作为血清素再摄取抑制剂的苯基哌嗪衍生物
CN1662497A (zh) N－[苯基(哌啶－2－基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用
CN1520293A (zh) 作为抗糖尿病药物的3-氟-吡咯烷类
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1608050A (zh) 哌嗪衍生物
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1922162A (zh) 烷基哌嗪－和烷基高哌嗪－羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN1729173A (zh) N－(吲哚乙基)环胺化合物
CN1322134A (zh) 作为速激肽受体拮抗剂的萘甲酰胺
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN101061123A (zh) 噻吩并吡啶酮化合物及治疗方法
CN1200939C (zh) 新的四氢吡啶,它们的制备方法以及含有它们的药物组合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1167682C (zh) 毒蕈碱拮抗剂
EP2480232B1 (en) Disubstituted ]4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
CN1708303A (zh) 具有5－ht和血清素再摄取抑制作用的作为抗抑郁药和抗焦虑药的吡啶烷基－氨基烷基－1h－吲哚衍生物
CN1461304A (zh) 作为双组织胺h1和h3促效剂或拮抗剂的取代的咪唑类化合物
CN1126738C (zh) 苯甲酰胺衍生物及含有它们的药物
CN1726215A (zh) 作为pde4抑制剂的[1,7]二氮杂萘
CN1164580C (zh) 用作5-羟色胺激活剂的二唑衍生物
CN1227230C (zh) Nmda受体配体的前药
CN1829516A (zh) 作为神经肽 y 5 ( n p y 5 )配体用于肥胖的治疗的 2 －‘4－(2－羟基甲基－苯基氨基)－哌啶－1－基↓－n－(9h－咔唑－3－基)－乙酰胺衍生物和有关化合物
CN1065269A (zh) 哒嗪酮乙酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication